Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer

Canonical prefoldin is a protein cochaperone composed of six di erent subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in...

ver descrição completa

Detalhes bibliográficos
Autores: Peñate Salas, Xenia, Praena Fernández, Juan Manuel, Romero Pareja, Pedro, Enguix Riego, María del Valle, Payán Bravo, Laura, Vieites Pérez-Quintela, Begoña, Chávez de Diego, Sebastián, López Guerra, José Luis
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/98291
Acesso em linha:https://hdl.handle.net/11441/98291
https://doi.org/10.3390/cancers12041052
Access Level:acceso abierto
Palavra-chave:Prefoldin
Metastasis
Survival
Non-small cell lung cancer
id ES_bb66dfdb31d78bc8900a8ed4bf521574
oai_identifier_str oai:idus.us.es:11441/98291
network_acronym_str ES
network_name_str España
repository_id_str
spelling Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancerPeñate Salas, XeniaPraena Fernández, Juan ManuelRomero Pareja, PedroEnguix Riego, María del VallePayán Bravo, LauraVieites Pérez-Quintela, BegoñaChávez de Diego, SebastiánLópez Guerra, José LuisPrefoldinMetastasisSurvivalNon-small cell lung cancerCanonical prefoldin is a protein cochaperone composed of six di erent subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients.EnfermeríaGenética2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/98291https://doi.org/10.3390/cancers12041052reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésCancers, 12 (1052), 1-9.info:eu-repo/semantics/openAccessoai:idus.us.es:11441/982912026-06-17T12:51:07Z
dc.title.none.fl_str_mv Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
title Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
spellingShingle Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
Peñate Salas, Xenia
Prefoldin
Metastasis
Survival
Non-small cell lung cancer
title_short Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
title_full Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
title_fullStr Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
title_full_unstemmed Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
title_sort Overexpression of canonical prefoldin associates with the risk of mortality and metastasis in non-small cell lung cancer
dc.creator.none.fl_str_mv Peñate Salas, Xenia
Praena Fernández, Juan Manuel
Romero Pareja, Pedro
Enguix Riego, María del Valle
Payán Bravo, Laura
Vieites Pérez-Quintela, Begoña
Chávez de Diego, Sebastián
López Guerra, José Luis
author Peñate Salas, Xenia
author_facet Peñate Salas, Xenia
Praena Fernández, Juan Manuel
Romero Pareja, Pedro
Enguix Riego, María del Valle
Payán Bravo, Laura
Vieites Pérez-Quintela, Begoña
Chávez de Diego, Sebastián
López Guerra, José Luis
author_role author
author2 Praena Fernández, Juan Manuel
Romero Pareja, Pedro
Enguix Riego, María del Valle
Payán Bravo, Laura
Vieites Pérez-Quintela, Begoña
Chávez de Diego, Sebastián
López Guerra, José Luis
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Enfermería
Genética
dc.subject.none.fl_str_mv Prefoldin
Metastasis
Survival
Non-small cell lung cancer
topic Prefoldin
Metastasis
Survival
Non-small cell lung cancer
description Canonical prefoldin is a protein cochaperone composed of six di erent subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial–mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/98291
https://doi.org/10.3390/cancers12041052
url https://hdl.handle.net/11441/98291
https://doi.org/10.3390/cancers12041052
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Cancers, 12 (1052), 1-9.
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418022583664640
score 15,300724

Registos relacionados